Clinical Trial Update: A Phase Ib Study Evaluating the Safety and Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations [Phase 1, Phase 2]

View source ↗

Summary

A Phase Ib/II study assessing the safety and tolerability of vitamin C in patients with intermediate- or high-risk myelodysplastic syndromes with TET2 mutations…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Vitamin C (ascorbic acid)

Snippet

Sponsor: NYU Langone Health | Conditions: Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-03-27